Circassia Pharmaceuticals Plc Notification of Major Interest in Shares (5772C)
April 18 2017 - 4:20AM
UK Regulatory
TIDMCIR
RNS Number : 5772C
Circassia Pharmaceuticals Plc
18 April 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------
1. Identity of the issuer or Circassia Pharmaceuticals
the underlying issuer plc
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- -----------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
------------------------------------------------------------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------------------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------------------------------------------
Other (please Passive change: threshold passed due X
specify): to an increase in the total number
of voting rights in the company
--------------------------------------------------------- -------------------------------------------
3. Full name of person(s) OppenheimerFunds, Inc.
subject to the
notification obligation:
(iii)
----------------------------------------------------------- ---------------------------------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
----------------------------------------------------------- ---------------------------------------------
5. Date of the transaction 12 April 2017
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- ---------------------------------------------
6. Date on which issuer 13 April 2017
notified:
----------------------------------------------------------- ---------------------------------------------
7. Threshold(s) that is/are 10% (decreased to 9.79%)
crossed or
reached: (vi, vii)
----------------------------------------------------------- ---------------------------------------------
8. Notified details:
Investor Relations Contact:
Circassia Pharmaceuticals plc
Northbrook House
Robert Robinson Avenue
The Oxford Science Park
Oxford OX4 4GA
United Kingdom
Tel +44 (0) 1865 405560
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the triggering
of to the triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- ----------------------------------- ------------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights (x)
Shares Voting
Rights
------------- ---------------- ----------------- -------------- ----------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ------------ ------------- -------------- --------- ------------ ------------ -----------
GB00BJVD3B28 32,540,657 32,540,657 32,540,657 9.79%
---------------- ----------------- -------------- --------- ------------ ------------ -----------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- -------------- --------------------------------- ------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- -------------- --------------- ---------------- ------------------------- -----------------------
Nominal Delta
--------------- -------------- --------------- ---------------- ------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
---------------------------------------------------- ----------------------------------------------------------------
32,540,657 9.79%
---------------------------------------------------- ----------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-----------------------------------------------------------------------------------------------------
OppenheimerFunds, Inc. ("OFI") is a registered investment
advisor with the U.S. SEC. Its ultimate parent company,
Massachusetts Mutual Life Insurance Company, qualifies
for disaggregation under FSA regulations. The shares
of the issuer are held by investment accounts managed
by OFI and its wholly owned subsidiary, OFI Global Asset
Management, Inc. ("OFIG").
Proxy Voting:
-----------------------------------------------------------------------------------------------------
10. Name of the proxy holder:
------------------------------------------------------------- --------------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
------------------------------------------------------------- --------------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
------------------------------------------------------------- --------------------------------------
13. Additional information: The percentage of holdings
noted above is based on the
updated total number of voting
rights in the company to
be 332,244,588, as disclosed
by the company on 12 April
2017 (Completion of the Transaction
and admission to trading
on the London Stock Exchange),
which has caused OFI to cross
below the 10% threshold.
------------------------------------------------------------- --------------------------------------
14. Contact name: Julien Cotta
------------------------------------------------------------- --------------------------------------
15. Contact telephone number: 01865 405560
------------------------------------------------------------- --------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLIPMLTMBBBMFR
(END) Dow Jones Newswires
April 18, 2017 05:20 ET (09:20 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Circassia Group Plc (London Stock Exchange): 0 recent articles
More Circassia Pharmaceuticals News Articles